Correction: Cantargia strengthens executive management in preparation for late-stage clinical development
Adjustment to regulatory in previous press release “Cantargia strengthens executive management in preparation for late-stage clinical development” Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the strengthening of its medical team. Dr. Roger Belusa has been appointed interim Chief Medical Officer (CMO), allowing his predecessor, Dr. Ignacio Garcia-Ribas, to take up a new position within Cantargia focusing on ongoing early phase clinical studies. Dr. Belusa has over 20 years of experience in various biotech and pharma companies developing cancer therapeutics.The new